Recombinant Human VEGF-A/VEGF165 Protein (N-His)

Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 is typically in the range of 1–6 ng/mL.

Vascular endothelial growth factor A (VEGF-A/VEGF165) is the prototypical pro-angiogenic member of the VEGF/PDGF growth factor family and a central regulator of both physiological and pathological angiogenesis. The 165-amino-acid isoform is the predominant secreted species; it forms a disulfide-linked homodimer that signals through VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1) and co-receptor neuropilin-1 on endothelial cells, driving proliferation, migration, survival and vascular permeability. Hypoxia and oncogenic signaling potently induce VEGF-A, which tumors exploit to build their blood supply — a process targeted clinically by bevacizumab and by the anti-VEGF biologics ranibizumab, aflibercept and faricimab used in wet age-related macular degeneration and other retinal vascular diseases. The human sequence is identical in cynomolgus macaque, so this protein serves cross-species (NHP) pharmacology studies directly. Bioactive recombinant VEGF165 is a workhorse reagent for endothelial culture, angiogenesis models and potency assays of anti-VEGF therapeutics.